News Charities call for shake-up in UK rare disease R&D LifeArc and Genetics Alliance UK have issued a call to the government to remove obstacles impeding R&D into rare diseases.
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
